NasdaqGS:ACADBiotechs
ACADIA Pharmaceuticals (ACAD) Stock Trades At A Discount To Earnings But Faces Concentrated Risk
ACADIA Pharmaceuticals has returned about 19.3% over the past five years, yet recent valuation checks still flag the stock as screening cheap relative to its fundamentals, even after a strong one month move and mixed shorter term performance.
Over a 5 year window, ACADIA Pharmaceuticals has delivered a 19.3% total return, which points to a moderate long term payoff rather than an outsized winner so far.
The recent positive opinion from the European Medicines Agency’s Committee for Medicinal...